Cost analysis of a growth guidance system for EOS in the US: An integrated health care delivery system perspective *Growing Rods vs SHILLA™*

Scott J Luhmann MD; Eoin M McAughey MSc; Stacey J Ackerman MSE PhD; David B Bumpass MD; Richard E McCarthy MD

*Sponsored in part by Medtronic. Medtronic was not involved in data analysis or interpretation.

Disclosures

Scott J Luhmann MD – Medtronic, Stryker, Nuvasive, Orthapedics, Globus Medical, Wolters Kluwer Eoin M McAughey MSc- Covance Stacey J Ackerman MSE PhD- Covance David B Bumpass MD- NASS, Medtronic, Acuity Surgical Richard E McCarthy MD- Medtronic

Current operative treatment

Current primary methods for operative treatment of EOS include:



Traditional Growing Rods: TGR



Magnetically Controlled Growing Rods: *MCGR*



Growth Guidance System: GGS

Lengthenings

- TGR requires repeated invasive surgical lengthenings that risk complications.
- MCGR lengthens noninvasively using a hand-held external remote controller.
- GGS obviates the need for active, distractive lengthenings.

Goal of Study



- Perform a cost analysis of GGS compared with TGR and MCGR for EOS
 - Taken from perspective of United States integrated health care delivery system
 - Over the complete 6-year episode of care from initial implantation (dual-rod construct) until final spinal fusion

Model methodology

 Based on <u>established method of cost analysis by Polly et al.</u> (2016) where MCGR was compared to TGR

Considered direct medical costs:

- Initial implantation
- Revisions due to device failure
- Surgical site infections
- Device exchange
- HCP visits (GGS every 6 months)
- Rod lengthenings (MCGR every 3 and TGR every 6 months)
- Removal and final fusion

Cumulative costs (2016 US dollars)

- <u>Parameters</u> in the decision-analytic model were derived from the most recent <u>peer-reviewed literature</u> – published data.
- Medicare payments were used as a proxy for provider costs.

Model assumptions

 The model assumes that clinical effectiveness (curve correction, increased thoracic height) is equivalent across devices

Additional assumptions:

- All devices exchanged at 3.8 years
- Deep SSI require device replacement and intravenous antibiotics
- Superficial infection requires oral antibiotics (paid by patient)
- Components replaced in a partial revision are the same across devices



Results over the 6-year episode of care/1000pts

- 1. Fewer invasive surgeries GGS vs TGR
- 2. Comparable # invasive surgeries GGS vs MCGR
- 3. Deep SSIs for GGS and MCGR substantially lower than TGR
- 4. Device failures (rod breakages) were least for TGR

Parameter (per 1,000 patients)	GGS	MCGR	TGR
Invasive surgeries	3,436	3,406	14,395
Deep SSIs	83	75	652
Device failures	436	406	395



Results: analysis



- Over a 6-year episode of care GGS had lower cumulative costs, saving an estimated 16% vs TGR and 18% vs MCGR
 - GGS initial insertion and exchange costs were offset by TGR lengthenings
 - MCGR had the highest initial insertion and exchange costs
 - Results were sensitive to changes in construct costs, rod breakage rates, months between lengthenings, and TGR lengthening setting of care.



Cost analysis to support decisionmaking

Limitations

This is a <u>cost analysis</u>, not a <u>cost-effectiveness</u> analysis

• Not considered:

- Family disruption for lengthenings
- Psychological stress of children and parents
- Effects of multiple anesthetics on children
- Compromised health-related quality of life associated with lengthenings
- MCGR rods that failed to lengthen





.

Conclusion

- From US integrated health care delivery system perspective,
 - <u>GGS</u> can provide a cost saving compared to <u>TGR</u> by obviating the need for repeated invasive surgical lengthenings that risk complications, such as deep SSIs
 - <u>GGS</u> can provide a cost saving vs <u>MCGR</u> due to <u>reduced construct costs</u> with a comparable rod fracture and deep SSI rate

Thank You from Arkansas

